HIV/AIDS HAART
Risk of triple-class antiretroviral drug failure declining in Denmark
Published in AIDS Weekly, August 8th, 2005
"To analyze the incidence, prevalence, and predictors for development of triple-class antiretroviral drug failure (TCF) in individuals infected with HIV," a population based "observational cohort study from January 1, 1995 to December 31, 2003" focused "on all 2722 recipients of highly active antiretroviral therapy (HAART) in Denmark."
"We used person-years analysis, Kaplan-Meier survival curves and Cox regression analysis. TCF was defined as a minimum of 120 days with viral load >1000 copies/ml on treatment with each of the three major drug classes," scientists writing...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-08-08)
More Articles from AIDS Weekly
- HIV/AIDS & Dengue Fever
Dendritic cell precursors are permissive to dengue virus and HIV infection - HIV/AIDS Drug Development
Artificial zinc finger fusions repress HIV-1 transcription and replication - HIV/AIDS Pathogenesis
Resting naive CD4+ cells massively infected/eliminated by X4-tropic SHIV - HIV/AIDS Treatment
High degree on agreement of HIV treatment recommendations derived from genotypes - Avian Influenza
International health entity stresses threat from Avian influenza has not ebbed - Awards
Virus research funded at Robarts by U.S.-based Howard Hughes Medical Institute - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
